钠-葡萄糖协同转运蛋白2抑制剂在肥胖相关性肾病中的作用及机制  

Effects and mechanisms of SGLT2 inhibitors in obesity-related glomerulopathy

作　　者：叶勇健 顾俊菲 YE Yongjian;GU Junfei(Department of Endocrinology,the Second Affiliated Hospital of Wannan Medical College,Wuhu 241001,China)

机构地区：[1]皖南医学院第二附属医院内分泌科,芜湖241001

出　　处：《中国临床保健杂志》2024年第5期705-710,共6页Chinese Journal of Clinical Healthcare

基　　金：安徽省自然科学基金青年项目(2308085QH260)。

摘　　要：随着全球肥胖患病率的上升,与肥胖相关的多种疾病,特别是肾脏疾病的发病率也在上升。肥胖是慢性肾脏疾病的独立危险因素,肥胖相关性肾病的病理生理机制复杂,涉及肾小球血流动力改变、肾素-血管紧张素-醛固酮系统过度激活、胰岛素抵抗、炎症反应及氧化应激等。钠-葡萄糖协同转运蛋白2抑制剂作为一种新型降血糖药物,已经被证实具有显著的肾脏获益。该文综述了肥胖相关性肾病的发病机制及钠-葡萄糖协同转运蛋白2抑制剂对其保护作用及机制。With increase of the global obesity prevalence,the incidence of many diseases associated with obesity,especially kidney disease,is also on the rise.Obesity itself is an independent risk factor for chronic kidney disease.The pathophysiology of obesity-related glomerulopathy is complex and involves changes in glomerular blood flow dynamics,excessive activation of the renin-angiotensin-aldosterone system,insulin resistance,inflammation,oxidative stress and so on.SGLT-2 inhibitors,as a novel class of antidiabetic drugs,have been proven to have significant renal benefits.This article reviews the pathogenic mechanisms of obesity-related glomerulopathy and the protective effects and mechanisms of SGLT-2 inhibitors on it.

关 键 词：肾病 肥胖症 钠-葡萄糖转运体2 

分 类 号：R589.2[医药卫生—内分泌] R692[医药卫生—内科学]